The Pectoralis (PECS2) Block Versus Intrathecal Morphine
Ultrasound-guided PECS2 (The Pectoralis) Block Versus Intrathecal Morphine for Postoperative Analgesia After Mastectomy
1 other identifier
interventional
50
1 country
1
Brief Summary
50 patients with American Society of Anesthesiologists (ASA) grade I to II, 18 to 60 years of age scheduled for Modified Radical Mastectomy surgery, Will be included in the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable postoperative-pain
Started Dec 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2023
CompletedFirst Posted
Study publicly available on registry
August 29, 2023
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedSeptember 13, 2023
September 1, 2023
7 months
April 29, 2023
September 8, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
post-operative analgesia.
the visual analog score will be evaluated postoperatively in all the patients in both groups
he visual analog score will be evaluated every 1 hour postoperatively.
Study Arms (2)
Morphine group (n= 25):
ACTIVE COMPARATORPECS group (n= 25):
ACTIVE COMPARATORInterventions
Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
Eligibility Criteria
You may qualify if:
- American Society of Anesthesiologists (ASA) grade I to II, 18 to 60 years of age scheduled for Modified Radical Mastectomy surgery.
You may not qualify if:
- \- Patient refusal.
- Patient with significant neurological , psychiatric or neuromuscular disease
- Alcoholism. Drug abuse.
- Pregnancy or lactating women.
- Suspected Coagulopathy.
- Morbid obesity.
- Known allergy to study medications.
- local infection at the block site
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University
Sohag, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of anesthesia and ICU
Study Record Dates
First Submitted
April 29, 2023
First Posted
August 29, 2023
Study Start
December 1, 2023
Primary Completion
July 1, 2024
Study Completion
September 1, 2024
Last Updated
September 13, 2023
Record last verified: 2023-09